Drugs /

fruquintinib

Back to Drugs List
Associated Genetic Biomarkers

Overview

Generic Name(s):
fruquintinib
NCI Definition [1]:
An orally available, small molecule inhibitor of vascular endothelial growth factor receptors (VEGFRs), with potential anti-angiogenic and antineoplastic activities. Upon oral administration, fruquintinib inhibits VEGF-induced phosphorylation of VEGFRs 1, 2, and 3 which may result in the inhibition of migration, proliferation and survival of endothelial cells, microvessel formation, the inhibition of tumor cell proliferation, and tumor cell death. Expression of VEGFRs may be upregulated in a variety of tumor cell types.

Clinical Trials

View Clinical Trials for fruquintinib

Fruquintinib has been investigated in 3 clinical trials, of which 3 are open and 0 are closed. Of the trials investigating fruquintinib, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 3 (1 open).

HER2 Deficient Expression, HER2 Negative, and ER Negative are the most frequent biomarker inclusion criteria for fruquintinib clinical trials.

Breast carcinoma, colorectal adenocarcinoma, and colorectal carcinoma are the most common diseases being investigated in fruquintinib clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Fruquintinib
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating fruquintinib and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
hmpl-013, vegfr-1/2/3 inhibitor hmpl-013, vegfr-1/2/3 inhibitor hmpl-013
Drug Categories [2]:
Tyrosine kinase inhibitors
Drug Target(s) [2]:
FLT1, FLT4, KDR
NCIT ID [1]:
C102852

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.